Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

November 30, 2032

Study Completion Date

December 1, 2032

Conditions

Juvenile Psoriatic Arthritis

Interventions

BIOLOGICAL

Secukinumab

Intravenous secukinumab

Trial Locations (3)

RECRUITING

Ann and Robert H Lurie Childs Hosp, Chicago

RECRUITING

Texas Arthritis Center, El Paso

RECRUITING

Legacy Emanuel Research Hosp Portland, Portland